Results 221 to 230 of about 368,924 (355)

Overdiagnosis of ductal carcinoma in situ by grade and definition in population-based screening: A modeling study. [PDF]

Breast
Poelhekken K, Greuter MJW, van der Vegt B, Dorrius MD, de Bock GH.   +4 more
europepmc   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Limitations of photodynamic therapy in HPV-positive Erythroplasia of Queyrat: A case of progression to carcinoma in situ. [PDF]

Medicine (Baltimore)
Lou Y, Duan Q, Yang L, Zhou P.
europepmc   +1 more source

Theranostic nanoplatform for high‐performance dual‐modal magnetic resonance imaging‐guided therapy of orthotopic hepatocellular carcinoma

BMEMat, EarlyView.
This article introduces a biomimetic Mn‐doped polydopamine nanoplatform (HAMM NPs) coated with cancer cell membranes. It enables targeted hepatocellular carcinoma theranostics via T1/T2 dual‐mode magnetic resonance imaging and tumor microenvironment‐triggered sonodynamic therapy/chemodynamic therapy, achieving potent antitumor efficacy in subcutaneous ...
Jiayin Lin, Wenbo Chen, Xiuqi Hou, Kai Wang, Fan Liu, Ruling Zhang, Zhong Cao, Jian Zheng   +7 more
wiley   +1 more source

Stromal collagen IV expression and risk of breast cancer death in ductal carcinoma in situ. [PDF]

BJC Rep
Rask G, Jansson M, Svensson J, Wiberg R, Wärnberg F, Billing O, Wadsten C, Sund M.   +7 more
europepmc   +1 more source

Focal Adhesion Kinase and Wnt Signaling Regulate Human Ductal Carcinoma In Situ Stem Cell Activity and Response to Radiotherapy [PDF]

, 2014
Kathryn Williams, Nigel Bundred, Göran Landberg, Robert B. Clarke, Gillian Farnie   +4 more
openalex   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ. [PDF]

Clin Cancer Res
Heiss BL, Chang E, Joeng HK, Fiero MH, Wang L, Hamed SS, Chiu HJ, Ricks TK, Koh EH, Dellibovi-Ragheb TA, Wang M, Lee C, Pierce WF, Leighton JK, Rahman NA, Tang S, Pazdur R, Amiri-Kordestani L, Kluetz PG, Suzman DL.   +19 more
europepmc   +1 more source

In-situ and invasive carcinoma within a phyllodes tumor associated with lymph node metastases [PDF]

, 2004
Jeremy Parfitt, C. Armstrong, Frances P. O’Malley, Joan M. Ross, Alan B. Tuck   +4 more
openalex   +1 more source

Vacancy defect‐induced electron homing breaks phosphodiester bonds for RNA depletion‐driven cancer therapy

BMEMat, EarlyView.
Illustration of 5% S‐vacancy Bi2S3 mediated phosphodiester bonds cleavage in RNA of hepatocellular carcinoma cells, which suppressing ERI3 expression, inhibiting cell proliferation and promoting apoptosis. Abstract Genome‐wide hypertranscription is a hallmark of malignant progression.
Chuncheng Yang, Zehao Shen, Guangming Xiang, Zhe Liu, Huaxin Liu, Jiabei Li, Ao Wang, Yelin Wu, Peiran Zhao, Xingwu Jiang, Jinghan Wang, Xiaoqing Jiang, Wenbo Bu   +12 more
wiley   +1 more source